Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019
Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019
Amsterdam, the Netherlands, Holzgerlingen, Germany and San Diego, CA, USA, May 15, 2019, 02:00 pm CEST / 08:00 am EDT - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, today published the invitation to its Annual General Shareholders’ Meeting (“AGM”) 2019.
Curetis will hold its AGM on June 27, 2019, at Steigenberger Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 01:00 pm CEST; local registration starts at 12:30 pm CEST.
In addition, Curetis will be offering electronic pre-voting from Friday, May 31, 2019, at 08:00 am CEST to June 20, 2019, at 05:30 pm CEST at .
A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available at .
Primary resolutions on the agenda of the AGM relate to nomination and the proposal to re-elect Curetis N.V. Management Board member Johannes Bacher for a period of three years. Moreover, the agenda provides for draft resolutions for the re-election of the Supervisory Board members William E. Rhodes III, Mario Crovetto, Prabhavathi Fernandes, Ph.D. for a further term of two years each and Dr. Rudy Dekeyser for another one-year term. Other items on the agenda include the designation of the Management Board as the company body authorized to issue new shares or grant rights to subscribe for shares in relation to strategic capital raising(s) and to not limit or exclude pre-emption rights on these shares.
###
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit and .
Legal Disclaimer
This document constitutes neither an offer to buy nor an offer to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “targets,” “may,” “will,” or “should” and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. 10
or
-
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. 64
Tel. 68
Attachment
